Before a drug is approved by the U.S. Food and Drug Administration (FDA), it must display each safety and efficacy. Nevertheless, the FDA doesn’t require an understanding a drug’s mechanism of motion for approval. This acceptance of results without explanation raises the query of whether the “black box” decision-making means of a secure and effective artificial intelligence model have to be fully explained in an effort to secure FDA approval.  

This topic was certainly one of many discussion points addressed on Monday, Dec. 4 through the MIT Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) AI and Health Regulatory Policy Conference, which ignited a series of discussions and debates amongst faculty; regulators from the USA, EU, and Nigeria; and industry experts regarding the regulation of AI in health. 

As machine learning continues to evolve rapidly, uncertainty persists as as to whether regulators can sustain and still reduce the likelihood of harmful impact while ensuring that their respective countries remain competitive in innovation. To advertise an environment of frank and open discussion, the Jameel Clinic event’s attendance was highly curated for an audience of 100 attendees debating through the enforcement of the Chatham House Rule, to permit speakers anonymity for discussing controversial opinions and arguments without being identified because the source. 

Moderately than hosting an event to generate buzz around AI in health, the Jameel Clinic’s goal was to create an area to maintain regulators apprised of essentially the most cutting-edge advancements in AI, while allowing faculty and industry experts to propose recent or different approaches to regulatory frameworks for AI in health, especially for AI use in clinical settings and in drug development. 

AI’s role in medicine is more relevant than ever, because the industry struggles with a post-pandemic labor shortage, increased costs (“Not a salary issue, despite common belief,” said one speaker), in addition to high rates of burnout and resignations amongst health care professionals. One speaker suggested that priorities for clinical AI deployment ought to be focused more on operational tooling somewhat than patient diagnosis and treatment. 

One attendee identified a “clear lack of education across all constituents — not only amongst developer communities and health care systems, but with patients and regulators as well.” Provided that medical doctors are sometimes the first users of clinical AI tools, plenty of the medical doctors present pleaded with regulators to seek the advice of them before taking motion. 

Data availability was a key issue for nearly all of AI researchers in attendance. They lamented the shortage of information to make their AI tools work effectively. Many faced barriers corresponding to mental property barring access or just a dearth of huge, high-quality datasets. “Developers can’t spend billions creating data, however the FDA can,” a speaker identified through the event. “There’s a price uncertainty that may lead to underinvestment in AI.” Speakers from the EU touted the event of a system obligating governments to make health data available for AI researchers. 

By the tip of the daylong event, most of the attendees suggested prolonging the discussion and praised the selective curation and closed environment, which created a singular space conducive to open and productive discussions on AI regulation in health. Once future follow-up events are confirmed, the Jameel Clinic will develop additional workshops of an identical nature to keep up the momentum and keep regulators within the loop on the newest developments in the sphere.

“The North Star for any regulatory system is safety,” acknowledged one attendee. “Generational thought stems from that, then works downstream.”